Terran Biosciences

Terran Biosciences is a private, platform-based biotechnology company pioneering a multi-faceted approach to neuroscience. Its strategy integrates late-stage clinical assets, a broad psychedelic and empathogen development program, advanced drug design capabilities, and a commercial AI software platform for neuroimaging. With a pipeline featuring several late-stage programs for schizophrenia and Alzheimer's disease, and key partnerships with Sanofi and Pierre Fabre, Terran is positioned to address significant unmet needs in psychiatry and neurology. The company operates as a pre-revenue entity, advancing its diverse portfolio through strategic licensing, internal R&D, and its first FDA-cleared software product.

Integrated platform combining a drug design & medicinal chemistry engine (specializing in prodrugs, extended-release formulations, and non-hallucinogenic psychoplastogens), an FDA-cleared AI-enabled cloud software for neuromelanin MRI analysis (NM-101), and GMP manufacturing capabilities for psychedelic compounds.

In schizophrenia, Terran competes with Karuna Therapeutics (Bristol Myers Squibb) and others advancing novel mechanisms. In psychedelics, it faces well-funded public companies like COMPASS Pathways (psilocybin for depression) and MAPS PBC (MDMA for PTSD). Terran's differentiation lies in its drug redesign platform (prodrugs, psychoplastogens) and its novel combination approach using 5-HT2A antagonists to modulate psychedelic effects, a largely uncontested strategy.